Bisphosphonates and osteonecrosis of the jaw: Moving from the bedside to the bench

Cells Tissues Organs

Volumn 189, Issue 1-4, 2008, Pages 289-294

  Allen, Matthew R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Bisphosphonate; Mandible; Osteonecrosis of the jaw; Remodeling suppression; Review

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; ZOLEDRONIC ACID;

ACTINOMYCES; ANGIOGENESIS; BONE MATRIX; BONE NECROSIS; BONE REMODELING; CONFERENCE PAPER; DOG; EXPERIMENTAL MODEL; HUMAN; JAW; MANDIBLE; MOUTH LESION; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; TOOTH INFECTION;

ANIMALS; BONE REMODELING; DIPHOSPHONATES; HUMANS; JAW DISEASES; NEOVASCULARIZATION, PATHOLOGIC; OSTEONECROSIS;

ANIMALIA; CANIS FAMILIARIS;

EID: 56749143817     PISSN: 14226405     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151371     Document Type: Conference Paper

References (39)

1. Allen, M.R., K. Iwata, R. Phipps, D.B. Burr (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: 872-879.
2. Allen, M.R., D.B. Burr (2007) Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res 22: 1759-1765.
3. Allen, M.R., D.B. Burr (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66: 987-994.
4. Balena, R., B.C. Toolan, M. Shea, A. Markatos, E.R. Myers, S.C. Lee, E.E. Opas, J.G. Seedor, H. Klein, D. Frankenfield (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 2577-2586.
5. Berenson, J.R., R.A. Vescio, L.S. Rosen, J.M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, A. Lipton (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7: 478-485.
6. Boyce, R.W., C.L. Paddock, J.R. Gleason, W.K. Sletsema, E.F. Eriksen (1995) The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10: 211-221.
7. Cao, Y., S. Mori, T. Mashiba, M.S. Westmore, L. Ma, M. Sato, T. Akiyama, L. Shi, S. Komatsubara, K. Miyamoto, H. Norimatsu (2002) Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17: 2237-2246.
8. Chavassieux, P.M., M.E. Arlot, C. Reda, L. Wei, A.J. Yates, P.J. Meunier (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100: 1475-1480.
9. Chesnut, C.H. 3rd, M.R. McClung, K.E. Ensrud, N.H. Bell, H.K. Genant, S.T. Harris, F.R. Singer, J.L. Stock, R.A. Yood, P.D. Delmas, et al. (1995) Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 99: 144-152.
10. Coxon, F.P., K. Thompson M.J. Rogers (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6: 307-312.
11. Enlow, D.H. (1962) Functions of the Haversian system. Am J Anat 110: 269-305.
12. Enlow, D.H. (1966) Osteocyte necrosis in normal bone. J Dent Res 45: 213.
13. Eriksen, E., D. Axelrod, F. Melsen (1994) Bone Histomorphometry. New York, Raven Press.
14. Eriksen, E.F., F. Melsen, E. Sod, I. Barton, A. Chines (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620-625.
15. Fournier, P., S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel P. Clezardin (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62: 6538-6544.
16. Frost, H.M. (1960) Micropetrosis. J Bone Joint Surg Am 42A: 144-150.
17. Garetto, L.P., J. Chen, J.A. Parr, W.E. Roberts (1995) Remodeling dynamics of bone supporting rigidly fixed titanium implants: a histomorphometric comparison in four species including humans. Implant Dent 4: 235-243.
18. Garetto, L.P., N.D. Tricker (1998) Remodeling of bone surrounding the implant interface; in Garetto, L.P., C.H. Turner, R.L. Duncan, D. B. Burr (eds): Bridging the Gap between Dental and Orthopaedic Implants: Proceedings of the 3rd Annual Indiana Conference, Indianapolis, Indiana. Indianapolis, Indiana University School of Dentistry and Indiana University School of Medicine.
19. Han, Z.H., S. Palnitkar, D.S. Rao, D. Nelson, A.M. Parfitt (1997) Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss. J Bone Miner Res 12: 498-508.
20. Hansen, T., M. Kunkel, A. Weber, C. James Kirkpatrick (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
21. Hewitt, R.E., A. Lissina, A.E. Green, E.S. Slay, D.A. Price, A.K. Sewell (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101-111.
22. Huja, S.S., S.A. Fernandez, K.J. Hill, Y. Li (2006) Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Rec A Discov Mol Cell Evol Biol 288: 1243-1249.
23. Jilka, R.L., R.S. Weinstein, A.M. Parfitt, S.C. Manolagas (2007) Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res 22: 1492-1501.
24. Li, J., S. Mori, Y. Kaji, T. Mashiba, J. Kawanishi, H. Norimatsu (1999) Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res 14: 969-979.
25. Marx, R.E. (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1117.
26. Mashiba, T., C.H. Turner, T. Hirano, M.R. Forwood, D.S. Jacob, C.C. Johnston, D.B. Burr (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29: 271-278.
27. Mehrotra, B., J. Fantasia, S. Nissel-Horowitz, S. Vinarsky, M. Sheth, S. Ruggiero (2003) Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. a case report. Proc Am Soc Clin Oncol 22: 3194.
28. Milhaud, G., M.L. Labat, Y. Moricard (1983) (Di chloromethylene) diphosphonate-induced impairment of T-lymphocyte function. Proc Natl Acad Sci USA 80: 4469-4473.
29. Odvina, C.V., J.E. Zerwekh, D.S. Rao, N. Maalouf, F.A. Gottschalk, C.Y. Pak (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301.
30. Peter, C.P., W.O. Cook, D.M. Nunamaker, M.T. Provost, J.G. Seedor, G.A. Rodan (1996) Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 14: 74-79.
31. Recker, R.R., S. Boonen, P. Garcia, J. Supronik, P. Peichl, D. Black, J. Krasnow, J. Chiodo, J. E.E. Gasser (2006) The effect of annual treatment with zoledronic acid 5 mg on bone remodeling: bone histomorphometry results from the HORIZON-PFT. J Bone Miner Res 21: S290.
32. Remaggi, F., M. Ferretti, V. Cane, D. Zaffe (1996) Histomorphological and chemico-physical analyses of the mineral matrix of micropetrotic human bone. Ann Anat 178: 223-227.
33. Rodan, G.A., H.A. Fleisch (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97: 2692-2696.
34. Sansoni, P., G. Passeri, F. Fagnoni, N. Mohagheghpour, G. Snelli, V. Brianti, E.G. Engleman (1995) Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10: 1719-1725.
35. Smith, S.Y., R.R. Recker, M. Hannan Muller, F. Bauss (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32: 45-55.
36. Verborgt, O., N.A. Tatton, R.J. Majeska, M.B. Schaffler (2002) Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? J Bone Miner Res 17: 907-914.
37. Wood, J., K. Bonjean, S. Ruetz, A. Bellahcene, L. Devy, J.M. Foidart, V. Castronovo J.R. Green (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061.
38. Yarom, N., R. Yahalom, Y. Shoshani, W. Hamed, E. Regev, S. Elad (2007) Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18: 1363-1370.
39. Zervas, K., E. Verrou, Z. Teleioudis, K. Vahtsevanos, A. Banti, D. Mihou, D. Krikelis, E. Terpos (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134: 620-623.